Champions Oncology, Inc.
CSBR- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0000771856
No open-market purchases or sales by Champions Oncology, Inc. insiders were filed in the last 90 days; 28 institutions reported holding it in 13F filings for Q2 2026, worth $36.3M in total; no superinvestor holds it.
Q3 2025 vs. Q2 2025
How the institutions holding Champions Oncology, Inc. changed between Q2 2025 and Q3 2025.
All holders in Q3 2025All holders in Q2 2025
| Measure | Q2 2025 | Q3 2025 | Change |
|---|---|---|---|
| Holders | 30 | 27 | −3 |
| Shares | 5.77M | 5.66M | −109.7K (−1.9%) |
| Value | $42.5M | $36.7M | −$5.88M (−13.8%) |
New holders (2)
Institutions that held Champions Oncology, Inc. at the end of Q3 2025 but not at the end of Q2 2025.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Citadel Advisors LLC | 16,326 | $105.7K | 0.00% |
| Whittier Trust Co | 800 | $5.04K | 0.00% |
Sold out (5)
Institutions that held Champions Oncology, Inc. at the end of Q2 2025 and filed for Q3 2025 without it.
| Institution | Shares, Q2 2025 | Value, Q2 2025 |
|---|---|---|
| Hillsdale Investment Management Inc. | 25,100 | $185.0K |
| Jane Street Group, LLC | 17,667 | $130.2K |
| XTX Topco Ltd | 14,034 | $103.4K |
| Lazard Asset Management LLC | 1,349 | $9.00K |
| Garde Capital, Inc. | 1 | $8 |